Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group
- Resource Type
- Article
- Source
- In
American Journal of Kidney Diseases 2010 55(1):50-60 - Subject
- Language
- ISSN
- 0272-6386